Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyridoxal 5'-Phosphate in PNPO Deficiency
NCT04706013Phase 3Active, not recruiting
- Sponsor
- Medicure Inc.
- Start
- Feb 2024
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of Tardoxal in pyridoxamine 5'-phosphate oxidase deficiency, sponsored by Medicure Inc.. Started Feb 2024; status: active, not recruiting.
02
Drugs
Tardoxal
03
Conditions
pyridoxamine 5'-phosphate oxidase deficiency
Beyond the preview
Go deeper on NCT04706013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04706013.